Skip to content

Advertisement

  • Poster presentation
  • Open Access

Screening for liver fibrosis in HIV-mono-infected patients with increased ALT comparing FibroScan with FIB-4

  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of the International AIDS Society200811 (Suppl 1) :P135

https://doi.org/10.1186/1758-2652-11-S1-P135

  • Published:

Keywords

  • Liver Fibrosis
  • Liver Stiffness
  • Recreational Drug
  • Advanced Fibrosis
  • Severe Fibrosis

Background

Elevated ALT values are frequently observed in HIV-mono-infected patients. Recent studies have reported cases of cryptogenic liver cirrhosis in HIV+ individuals. Other possible explanations are non-alcoholic/alcoholic steatohepatitis and drug toxicity. We have used two non-invasive methods, liver elastometry (FibroScan) and a serologic fibrosis index (FIB-4), for liver fibrosis screening in a single centre.

Methods

HIV-infected patients without hepatitis B and C co-infection with at least one elevated ALT in 2007/2008 (males >50 U/l, females >35 U/l) were selected for liver elastometry by FibroScan (Echosens, Paris). Antiretroviral medication, co-medication, alcohol consumption, smoking, recreational drug use and BMI were assessed. Liver stiffness was classified as <7.2 kPa (no/minimal fibrosis), 7.2–12.5 kPa (moderate fibrosis), >12.5 -17.6 kPa (severe fibrosis), >17.6 kPa (cirrhosis). FibroScans were performed by two trained and experienced investigators (high inter-observer-correlation, r = 0.80, p < .05). FIB-4 index (age[years] × AST[U/l])/(platelets [10^9/l] × ALT^0.5 [U/l]) was used for serologic fibrosis assessment. For statistical evaluation, SPSS 15.0 was used.

Summary of results

Out of 1,098 HIV-infected individuals, 227 had increased ALT without hepatitis co-infection; 81 patients were consecutively screened by FibroScan. A valid elastometry was obtained in 79/81 (98%) patients. 76/81 were male, median age was 45 years (27–71 years), median BMI 24.6 kg/sqm (19.1–33.7 kg/sqm), median ALT 60 U/l (38–144 U/l). 70/81 (86%) were on antiretroviral therapy with median duration of 76 months. HIV-RNA was <40 copies/ml in 63/70 treated patients (90%). Median CD4+ cells were 618/μl (130–1635 cells/μl). Alcohol consumption was >24 g/day (males) or >12 g/day (females) in 11% of patients, 41% were smokers, and 17% reported consumption of recreational drugs. Median liver stiffness was 5.2 kPa (3.1 – 8.8 kPa). No/minimal fibrosis was found in 70/79 (89%), moderate fibrosis in 9/79 (11%). No patient had severe fibrosis or cirrhosis. With FIB-4 62/81 (77%) patients had no/minimal fibrosis, 18/81 (22%) moderate fibrosis and 1/81 (1%) advanced fibrosis.

Conclusion

In this ongoing study about 20% of HIV-mono-infected patients had elevated ALT. Advanced liver fibrosis was rare in this cohort of HIV-mono-infected individuals, and there is good agreement between FibroScan and FIB-4.

Authors’ Affiliations

(1)
Center for HIV and Hepatogastroenterology, Duesseldorf, Germany

Copyright

© Mauss et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement